Your browser doesn't support javascript.
Identification of SARS-CoV-2 Nucleocapsid and Spike T-Cell Epitopes for Assessing T-Cell Immunity.
Lee, Eunok; Sandgren, Kerrie; Duette, Gabriel; Stylianou, Vicki V; Khanna, Rajiv; Eden, John-Sebastian; Blyth, Emily; Gottlieb, David; Cunningham, Anthony L; Palmer, Sarah.
  • Lee E; Centre for Virus Research, The Westmead Institute for Medical Research, Westmead, New South Wales, Australia eunok.lee@sydney.edu.au.
  • Sandgren K; Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Camperdown, New South Wales, Australia.
  • Duette G; Centre for Virus Research, The Westmead Institute for Medical Research, Westmead, New South Wales, Australia.
  • Stylianou VV; Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Camperdown, New South Wales, Australia.
  • Khanna R; Centre for Virus Research, The Westmead Institute for Medical Research, Westmead, New South Wales, Australia.
  • Eden JS; Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Camperdown, New South Wales, Australia.
  • Blyth E; Centre for Virus Research, The Westmead Institute for Medical Research, Westmead, New South Wales, Australia.
  • Gottlieb D; Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Camperdown, New South Wales, Australia.
  • Cunningham AL; Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.
  • Palmer S; QIMR Berghofer Centre for Immunotherapy and Vaccine Development, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
J Virol ; 95(6)2021 02 24.
Article in English | MEDLINE | ID: covidwho-1150200
ABSTRACT
Developing optimal T-cell response assays to severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) is critical for measuring the duration of immunity to this disease and assessing the efficacy of vaccine candidates. These assays need to target conserved regions of SARS-CoV-2 global variants and avoid cross-reactivity to seasonal human coronaviruses. To contribute to this effort, we employed an in silico immunoinformatics analysis pipeline to identify immunogenic peptides resulting from conserved and highly networked regions with topological importance from the SARS-CoV-2 nucleocapsid and spike proteins. A total of 57 highly networked T-cell epitopes that are conserved across geographic viral variants were identified from these viral proteins, with a binding potential to diverse HLA alleles and 80 to 100% global population coverage. Importantly, 18 of these T-cell epitope derived peptides had limited homology to seasonal human coronaviruses making them promising candidates for SARS-CoV-2-specific T-cell immunity assays. Moreover, two of the NC-derived peptides elicited effector/polyfunctional responses of CD8+ T cells derived from SARS-CoV-2 convalescent patients.IMPORTANCE The development of specific and validated immunologic tools is critical for understanding the level and duration of the cellular response induced by SARS-CoV-2 infection and/or vaccines against this novel coronavirus disease. To contribute to this effort, we employed an immunoinformatics analysis pipeline to define 57 SARS-CoV-2 immunogenic peptides within topologically important regions of the nucleocapsid (NC) and spike (S) proteins that will be effective for detecting cellular immune responses in 80 to 100% of the global population. Our immunoinformatics analysis revealed that 18 of these peptides had limited homology to circulating seasonal human coronaviruses and therefore are promising candidates for distinguishing SARS-CoV-2-specific immune responses from pre-existing coronavirus immunity. Importantly, CD8+ T cells derived from SARS-CoV-2 survivors exhibited polyfunctional effector responses to two novel NC-derived peptides identified as HLA-binders. These studies provide a proof of concept that our immunoinformatics analysis pipeline identifies novel immunogens which can elicit polyfunctional SARS-CoV-2-specific T-cell responses.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: CD8-Positive T-Lymphocytes / Epitopes, T-Lymphocyte / Spike Glycoprotein, Coronavirus / Coronavirus Nucleocapsid Proteins / SARS-CoV-2 Type of study: Diagnostic study / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Language: English Year: 2021 Document Type: Article Affiliation country: Jvi.02002-20

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: CD8-Positive T-Lymphocytes / Epitopes, T-Lymphocyte / Spike Glycoprotein, Coronavirus / Coronavirus Nucleocapsid Proteins / SARS-CoV-2 Type of study: Diagnostic study / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Language: English Year: 2021 Document Type: Article Affiliation country: Jvi.02002-20